These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26165588)

  • 1. Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
    Moreira DM; Bostwick DG; Andriole GL; Peterson BL; Cohen HJ; Castro-Santamaria R; Freedland SJ
    J Urol; 2015 Nov; 194(5):1241-6. PubMed ID: 26165588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study.
    Moreira DM; Nickel JC; Gerber L; Muller RL; Andriole GL; Castro-Santamaria R; Freedland SJ
    Cancer; 2014 Jan; 120(2):190-6. PubMed ID: 24323568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies.
    Freitas D; Andriole GL; Freedland SJ; Neto BS; Moreira DM
    Urology; 2019 Jul; 129():160-164. PubMed ID: 30914334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study.
    Moreira DM; Fleshner NE; Freedland SJ
    J Urol; 2015 Nov; 194(5):1258-63. PubMed ID: 25988518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
    Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
    BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study.
    Moreira DM; Nickel JC; Andriole GL; Castro-Santamaria R; Freedland SJ
    Prostate; 2015 Sep; 75(13):1492-8. PubMed ID: 26184556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations.
    Moreira DM; Andriole GL; Nickel JC; Roehrborn CG; Castro-Santamaria R; Freedland SJ
    World J Urol; 2017 Oct; 35(10):1525-1530. PubMed ID: 28396999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extent of Baseline Prostate Atrophy Is Associated With Lower Incidence of Low- and High-grade Prostate Cancer on Repeat Biopsy.
    Freitas DM; Andriole GL; Castro-Santamaria R; Freedland SJ; Moreira DM
    Urology; 2017 May; 103():161-166. PubMed ID: 28024967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens.
    Moreira DM; de O Freitas DM; Nickel JC; Andriole GL; Castro-Santamaria R; Freedland SJ
    Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):413-417. PubMed ID: 28585572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline prostate atrophy is associated with lower tumor volume in men with prostate cancer on repeat biopsy.
    Moreira DM; Andriole GL; Castro-Santamaria R; Freedland SJ
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):106-112. PubMed ID: 29203895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
    Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
    J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen.
    Quentin M; Blondin D; Arsov C; Schimmöller L; Hiester A; Godehardt E; Albers P; Antoch G; Rabenalt R
    J Urol; 2014 Nov; 192(5):1374-9. PubMed ID: 24866597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.
    Fleshner NE; Lucia MS; Egerdie B; Aaron L; Eure G; Nandy I; Black L; Rittmaster RS
    Lancet; 2012 Mar; 379(9821):1103-11. PubMed ID: 22277570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
    Andriole GL; Bostwick D; Brawley OW; Gomella L; Marberger M; Montorsi F; Pettaway C; Tammela TL; Teloken C; Tindall D; Freedland SJ; Somerville MC; Wilson TH; Fowler I; Castro R; Rittmaster RS;
    J Urol; 2011 Jan; 185(1):126-31. PubMed ID: 21074214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
    Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of atrophy in baseline prostate biopsy and lower prostate cancer grade in radical prostatectomy specimens.
    Freitas DMO; Andriole GL; Castro-Santamaria R; Freedland SJ; Moreira DM
    Scand J Urol; 2018; 52(5-6):328-332. PubMed ID: 30762450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study.
    Naha U; Nickel JC; Andriole GL; Freedland SJ; Moreira DM
    J Urol; 2021 Mar; 205(3):755-760. PubMed ID: 33080149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride.
    Muller RL; Gerber L; Moreira DM; Andriole G; Hamilton RJ; Fleshner N; Parsons JK; Freedland SJ
    Eur Urol; 2013 Jun; 63(6):1115-21. PubMed ID: 23541458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
    Andriole G; Bostwick D; Brawley O; Gomella L; Marberger M; Tindall D; Breed S; Somerville M; Rittmaster R;
    J Urol; 2004 Oct; 172(4 Pt 1):1314-7. PubMed ID: 15371831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
    Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
    J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.